AU2003270690B2 - Lactoferrin compositions and methods of wound treatment - Google Patents

Lactoferrin compositions and methods of wound treatment Download PDF

Info

Publication number
AU2003270690B2
AU2003270690B2 AU2003270690A AU2003270690A AU2003270690B2 AU 2003270690 B2 AU2003270690 B2 AU 2003270690B2 AU 2003270690 A AU2003270690 A AU 2003270690A AU 2003270690 A AU2003270690 A AU 2003270690A AU 2003270690 B2 AU2003270690 B2 AU 2003270690B2
Authority
AU
Australia
Prior art keywords
lactoferrin
wound
rhlf
composition
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003270690A
Other languages
English (en)
Other versions
AU2003270690A1 (en
Inventor
Jose Engelmayer
Atul Varadhachary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Publication of AU2003270690A1 publication Critical patent/AU2003270690A1/en
Application granted granted Critical
Publication of AU2003270690B2 publication Critical patent/AU2003270690B2/en
Priority to AU2009225309A priority Critical patent/AU2009225309B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU2003270690A 2002-09-16 2003-09-16 Lactoferrin compositions and methods of wound treatment Ceased AU2003270690B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009225309A AU2009225309B2 (en) 2002-09-16 2009-10-13 Lactoferrin compositions and methods of wound treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41098102P 2002-09-16 2002-09-16
US60/410,981 2002-09-16
PCT/US2003/029069 WO2004024180A1 (en) 2002-09-16 2003-09-16 Lactoferrin compositions and methods of wound treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009225309A Division AU2009225309B2 (en) 2002-09-16 2009-10-13 Lactoferrin compositions and methods of wound treatment

Publications (2)

Publication Number Publication Date
AU2003270690A1 AU2003270690A1 (en) 2004-04-30
AU2003270690B2 true AU2003270690B2 (en) 2009-07-30

Family

ID=31994228

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003270690A Ceased AU2003270690B2 (en) 2002-09-16 2003-09-16 Lactoferrin compositions and methods of wound treatment
AU2009225309A Expired - Fee Related AU2009225309B2 (en) 2002-09-16 2009-10-13 Lactoferrin compositions and methods of wound treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009225309A Expired - Fee Related AU2009225309B2 (en) 2002-09-16 2009-10-13 Lactoferrin compositions and methods of wound treatment

Country Status (12)

Country Link
US (3) US7524814B2 (de)
EP (2) EP2298338B1 (de)
JP (1) JP4516844B2 (de)
CN (1) CN1694720A (de)
AT (1) ATE497778T1 (de)
AU (2) AU2003270690B2 (de)
CA (1) CA2499014A1 (de)
DE (1) DE60335997D1 (de)
DK (2) DK1545587T3 (de)
ES (1) ES2358645T3 (de)
SI (2) SI1545587T1 (de)
WO (1) WO2004024180A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
WO2003094952A1 (en) * 2002-05-10 2003-11-20 Agennix Incorporated Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2003099207A2 (en) * 2002-05-24 2003-12-04 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
SI1545587T1 (sl) 2002-09-16 2011-06-30 Agennix Inc Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede
US20040152624A1 (en) * 2002-12-06 2004-08-05 Atul Varadhachary Oral lactoferrin in the treatment of sepsis
AU2003296447A1 (en) 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
WO2005046571A2 (en) * 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
DK1793859T3 (da) * 2004-08-20 2009-06-22 Smithkline Beecham Corp Behandling af oral og intestinal mucositis ved indgivelse af humant IL-18
US7183381B2 (en) 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
US8263105B2 (en) * 2004-12-01 2012-09-11 Tyco Healthcare Group Lp Biomaterial drug delivery and surface modification compositions
ITRM20040638A1 (it) 2004-12-24 2005-03-24 Advance Holdings Ltd Gel piastrinico semisintetico e metodo per la sua preparazione.
US20060240116A1 (en) * 2005-04-22 2006-10-26 David Jolley Bioactive factors in wound healing topical compositions and methods
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007022537A2 (en) * 2005-08-19 2007-02-22 Agennix Incorporated Use of lactoferrin as a chemokine and a chemotactic modulator
US20070059300A1 (en) * 2005-09-12 2007-03-15 Zoltan Laboratories Llc Compounds and compositions to control abnormal cell growth
EP1968627B1 (de) * 2005-11-18 2014-12-10 Glanbia Nutritionals (Ireland) Limited Zusammensetzungen zur unterbrechung und unterdrückung der rekonstitution eines wundbiofilms
US20070179084A1 (en) * 2006-01-30 2007-08-02 Nation Chiao Tung University Process for reducing the concentration of blood glucose in a diabetic patient
ATE449617T1 (de) * 2006-02-02 2009-12-15 Euro Celtique Sa Hydrogel für wundbehandlung
US20100329995A1 (en) * 2006-02-21 2010-12-30 Ventria Bioscience Compositions containing lactoferrin, and methods of using same to promote growth of skin cells
ES2704454T3 (es) * 2006-07-03 2019-03-18 Perraudin Jean Paul Composiciones antimicrobianas que comprenden hipohalito y/o hipotiocianito y sus usos
GB0616580D0 (en) * 2006-08-21 2006-09-27 Novathera Ltd Composite material
EP2061486A4 (de) * 2006-09-13 2011-11-16 Southeastern Medical Technologies Llc Verfahren und zusammensetzungen zum verschliessen und anheften von biologischem gewebe und medizinische anwendungen
US10143694B2 (en) * 2006-10-27 2018-12-04 Matthew H. Kopacki Advanced formulations and therapies for treating hard-to-heal wounds
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
WO2009123720A2 (en) * 2008-04-01 2009-10-08 Southeastern Medical Technologies, Llc Methods and compositions for medical articles produced from proteinaceous compounds
EP2141242A1 (de) * 2008-07-04 2010-01-06 Universität des Saarlandes Synthetische Wegenzyme zur Herstellung von Argyrinen
US8614189B2 (en) * 2008-09-24 2013-12-24 University Of Connecticut Carbon nanotube composite scaffolds for bone tissue engineering
US20110015587A1 (en) * 2009-07-14 2011-01-20 Tumey David M Irrigation Device and Method Using Same
JP2011020973A (ja) * 2009-07-17 2011-02-03 Nrl Pharma Inc 難治性の皮膚潰瘍治療用の医薬組成物、及び、皮膚潰瘍予防用化粧料
WO2011066175A1 (en) * 2009-11-25 2011-06-03 Nestec S.A. Nutritional compositions including a high protein component and exogenous nucleotides
WO2011143187A2 (en) 2010-05-10 2011-11-17 University Of Connecticut Lactoferrin -based biomaterials for tissue regeneration and drug delivery
JP2013530990A (ja) * 2010-07-01 2013-08-01 ブライエン ホールデン ビジョン インスティテュート 創傷治療に係るラクトフェリンの配列、組成物、及び方法
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
US20120171231A1 (en) * 2010-12-29 2012-07-05 Anja Wittke Use of nutritional compositions including lactoferrin in stimulating immune cells
KR101748907B1 (ko) * 2011-01-26 2017-06-19 유키지루시 메그밀크 가부시키가이샤 감각 개선제
EP2670417A4 (de) * 2011-01-31 2014-07-09 Us Army Verfahren und zusammensetzungen zur behandlung bakterieller infektionen mit eisenchelatoren
EP2957304B1 (de) * 2011-08-31 2017-02-15 KCI Licensing, Inc. Systeme und verfahren für behandlungen und wundausschneidungen mit reduziertem druck
CA2890757C (en) 2012-11-14 2021-10-26 Smith & Nephew, Inc. Stable thermolysin hydrogel
JP6275955B2 (ja) * 2013-04-25 2018-02-07 松尾 敏郎 塩化マグネシウムを摂取する人を除いた生物の細胞の活性化方法
CZ308554B6 (cs) * 2013-10-21 2020-11-25 Univerzita Tomáše Bati ve Zlíně Hydrogelová kosmetická nebo farmaceutická kompozice s účinnějším působením v ní obsažených biologicky aktivních látek z hlediska antimikrobiálních účinků
EP3197475B1 (de) 2014-09-24 2020-03-18 Tower S.r.l. u.s. Zusammensetzungen und verfahren zur vorbeugung und/oder behandlung von infektionen und entzündungen
RU2658707C1 (ru) * 2016-12-28 2018-06-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ восстановления кожного покрова
US20200024329A1 (en) 2018-07-17 2020-01-23 Bradley G. Thompson Methods for regulating endogenous production of lactoferrin and sub-peptides thereof
JP7140431B2 (ja) * 2018-07-31 2022-09-21 レモネックス インコーポレイテッド 傷治療用の医薬組成物
US20220016220A1 (en) * 2018-12-11 2022-01-20 Universita' Degli Studi Di Salerno Composition for the treatment of skin lesions
CN110075054A (zh) * 2019-06-06 2019-08-02 山东天源人乳库科技发展有限公司 一种来源于人乳的人源性生长因子修复制剂及其制备方法
BE1027357B1 (nl) * 2019-06-12 2021-01-18 Vanlommel Maria Kristel Voedingssupplement voor versnelde genezing
CN110680949B (zh) * 2019-10-18 2021-06-29 中山大学 一种基于母乳的创伤敷料的制备方法和应用
AU2022333079A1 (en) * 2021-08-23 2024-04-04 Lactea Therapeutics Llc Lactoferrin compositions and methods of use
CN113576938B (zh) * 2021-08-26 2022-07-08 广东丸美生物技术股份有限公司 一种口腔护理组合物及其应用
CN116421775A (zh) * 2023-04-21 2023-07-14 青岛优瑞达生物科技有限公司 一种乳铁蛋白凝胶敷料、制备方法和应用
CN116251224B (zh) * 2023-05-16 2023-09-12 江苏正大天创生物工程有限公司 一种乳铁蛋白凝胶敷料及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561109A (en) * 1990-11-13 1996-10-01 Santen Pharmaceutical Co., Ltd. Method for the healing of wounds caused by corneal injury
US5576299A (en) * 1992-03-02 1996-11-19 Immuno Japan, Inc. Formulated medicine for treatment and prevention of opportunistic infectious diseases complicated by infection with lentivirus
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
US6333311B1 (en) * 1997-02-03 2001-12-25 Pharming Useful properties of human lactoferrin and variants thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4788488A (en) * 1986-10-14 1988-11-29 Drexelbrook Controls, Inc. Continuous condition sensing system
US4783488A (en) * 1987-01-31 1988-11-08 Bausch & Lomb Incorporated Contact lens wetting solution
US4977137B1 (en) * 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US5571691A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5766939A (en) * 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US6100054A (en) 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5849881A (en) * 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US5571697A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5198419A (en) * 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
JP3395904B2 (ja) * 1990-01-12 2003-04-14 ニューヨーク ソサイエティ フォー ザ リリーフ オヴ ザ ラプチャード アンド クリップルド，メインテイニング ザ ホスピタル フォー スペシャル サージェリー 創傷治癒および組織修復を高める方法
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
GB2248842A (en) * 1990-10-16 1992-04-22 American Cyanamid Co Film-forming polymer compositions
JPH06508371A (ja) 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
WO1993013216A1 (en) 1991-12-24 1993-07-08 The President And Fellows Of Harvard College Site-directed mutagenesis of dna
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
NL9220019A (nl) * 1992-04-10 1994-04-05 Vnii Med Polimerov Farmaceutische samenstelling.
ZA932568B (en) * 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
JPH07196529A (ja) * 1993-12-29 1995-08-01 Morinaga Milk Ind Co Ltd 創傷治癒剤、化粧料および養毛剤
WO1995022258A2 (en) 1994-02-16 1995-08-24 Pharming Bv Isolation of lactoferrin from milk
JP3746081B2 (ja) 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
US5827874A (en) * 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
US20020016289A1 (en) * 1995-06-01 2002-02-07 Orla M. Conneely Methods for treatment and prevention of helicobacter pylori infection using lactoferrin
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
GB2321191B (en) * 1997-01-17 2000-09-27 Johnson & Johnson Medical Peptides for use in wound treatment
WO1998044940A1 (en) * 1997-04-10 1998-10-15 Agennix, Inc. Use of lactoferin in the treatment of allergen induced disorders
JP3856908B2 (ja) * 1997-06-06 2006-12-13 田辺製薬株式会社 褥瘡及び／又は創傷治療剤
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6432415B1 (en) * 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
WO2002100445A1 (en) 2001-06-13 2002-12-19 The University Of Sydney Treatment and composition for wound healing
WO2003094952A1 (en) * 2002-05-10 2003-11-20 Agennix Incorporated Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2003099207A2 (en) * 2002-05-24 2003-12-04 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
SI1545587T1 (sl) * 2002-09-16 2011-06-30 Agennix Inc Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede
AU2003291206A1 (en) 2002-12-04 2004-06-23 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
US20040152624A1 (en) 2002-12-06 2004-08-05 Atul Varadhachary Oral lactoferrin in the treatment of sepsis
AU2003296447A1 (en) 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
AU2003293500A1 (en) * 2002-12-12 2004-07-09 Agennix Incorporated Lactoferrin in the reduction of pain
WO2004103285A2 (en) 2003-05-14 2004-12-02 Agennix Incorporated Lactoferrin in the treatment of diabetes mellitus
WO2005046571A2 (en) 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
US5561109A (en) * 1990-11-13 1996-10-01 Santen Pharmaceutical Co., Ltd. Method for the healing of wounds caused by corneal injury
US5576299A (en) * 1992-03-02 1996-11-19 Immuno Japan, Inc. Formulated medicine for treatment and prevention of opportunistic infectious diseases complicated by infection with lentivirus
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
US6333311B1 (en) * 1997-02-03 2001-12-25 Pharming Useful properties of human lactoferrin and variants thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Berkel, et al. Biochem J. Vol 328: 145-151 (1997) *
Legrand, et al. Biochem J. Vol 327: 841-846 (1997) *

Also Published As

Publication number Publication date
US7524814B2 (en) 2009-04-28
JP2006503044A (ja) 2006-01-26
US8030272B2 (en) 2011-10-04
US20040142037A1 (en) 2004-07-22
EP1545587A1 (de) 2005-06-29
JP4516844B2 (ja) 2010-08-04
CA2499014A1 (en) 2004-03-25
SI1545587T1 (sl) 2011-06-30
DK2298338T3 (da) 2012-09-24
EP1545587B1 (de) 2011-02-09
EP2298338B1 (de) 2012-08-22
CN1694720A (zh) 2005-11-09
DE60335997D1 (de) 2011-03-24
AU2003270690A1 (en) 2004-04-30
WO2004024180A1 (en) 2004-03-25
ES2358645T3 (es) 2011-05-12
ATE497778T1 (de) 2011-02-15
US20120010150A1 (en) 2012-01-12
EP1545587A4 (de) 2009-06-17
DK1545587T3 (da) 2011-05-09
US20090253627A1 (en) 2009-10-08
EP2298338A1 (de) 2011-03-23
US8247373B2 (en) 2012-08-21
SI2298338T1 (sl) 2012-11-30
AU2009225309B2 (en) 2012-06-14
AU2009225309A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
AU2003270690B2 (en) Lactoferrin compositions and methods of wound treatment
KR100444417B1 (ko) 성장인자를함유하는겔제형
US6720009B2 (en) Matrix protein compositions for treating infection
US6979670B1 (en) Matrix protein compositions for grafting
CA2322215C (en) Matrix protein compositions for wound healing
JPH0543453A (ja) 創傷治癒促進用局所用徐放性製剤
Shakhakarmi et al. EGF, a veteran of wound healing: Highlights on its mode of action, clinical applications with focus on wound treatment, and recent drug delivery strategies
JP4726300B2 (ja) 移植用マトリックス・タンパク質組成物
JP3624158B2 (ja) ヒト上皮成長因子を含有する皮膚外用剤組成物
Shi et al. Recent progresses of collagen dressings for chronic skin wound healing
US20030105007A1 (en) PDGF-betabeta and fibronectin combined in a solid wound dressing for the treatment of wounds
CN116832143A (zh) 一种用于全层皮肤损伤创面愈合的pdgf制剂
TW202202145A (zh) 促進傷口癒合的有機鍺藥物及其使用方法
WO2007018846A2 (en) Use of interferon- tau for reduction of scar tissue formation
CN116920077A (zh) 血小板衍生生长因子在制备褥疮治疗药物中的应用
MXPA00008240A (en) Matrix protein compositions for wound healing
CN1689641A (zh) 生长激素的非注射性制剂及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired